Rheumatic diseases include a wide spectrum of diseases involving musculoskeletal and immune system. Spinal disorders, whether mechanical or inflammatory, are main manifestations in daily clinical practice of rheumatologists, neurologists, orthopaedics, and general physicians.
Spondyloarthritis (SpA), typically ankylosing spondylitis (AS), is one of the major rheumatic spinal disorders. The pathogenesis of SpA involved many interaction domains including genes, immunity, mechanical stress, infection, and other environmental factors [1] . Genetic backgrounds, such as HLA-B27, B60, ERAP-1, and IR23R, play major roles in the initiation and pathogenesis of SpA. These multifactorial geneenvironmental interaction mechanisms lead to variable clinical phenotypes of this complex diseases spectrum, mainly arthritis in spine, sacroiliac joints, and peripheral joints, but also extra-articular manifestations, such as uveitis, psoriasis, and bowel inflammation (Figure 1) .
The Assessment in Spondyloarthritis International Society (ASAS), an international task force, had generated new ASAS criteria for axial and peripheral SpA by predominant pattern of clinical manifestations in 2009 [2] and 2011 [3] . These classification criteria aimed to standardize definition of this diseases spectrum for clinical researches and emphasized early detection of SpA by usage of magnetic resonance imaging (MRI) in sacroiliac joints and human leukocyte antigen-(HLA-) B27 in diagnosis of SpA. A new disease term, nonradiographic axial SpA (nr-ax SpA), was thus created to describe patients who fulfilled the 2009 ASAS criteria for axial SpA but not the 1984 modified New York criteria for AS [4] . However, there are still many debates about the scope of this new term, nr-ax SpA, including the definition, disease natural course, clinical diagnosis, and management strategies.
Treatment goals for SpA are maintenance of physical function, disease activity, and prevention of radiographic progression to ankylosis. Current effective therapies to control SpA disease activity are available, including exercise and physical therapy [5] , nonsteroidal anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic drugs (DMARDs) such as sulfasalazine, and biological agents, mainly TNF blockers. Potential experimental therapies are promising, including IL17 blockers and IL23 blockers [6] .
In this special issue, 16 articles were accepted, while the other 21 were rejected. 
